- Home
- MHK vs LEGN Comparison
MHK vs LEGN Comparison
Compare MHK & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHK
- LEGN
- Stock Information
- Founded
- MHK 1988
- LEGN 2014
- Country
- MHK United States
- LEGN United States
- Employees
- MHK N/A
- LEGN N/A
- Industry
- MHK Home Furnishings
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- MHK Consumer Discretionary
- LEGN Health Care
- Exchange
- MHK Nasdaq
- LEGN Nasdaq
- Market Cap
- MHK 6.3B
- LEGN 5.4B
- IPO Year
- MHK 1992
- LEGN 2020
- Fundamental
- Price
- MHK $99.50
- LEGN $34.00
- Analyst Decision
- MHK Buy
- LEGN Strong Buy
- Analyst Count
- MHK 14
- LEGN 12
- Target Price
- MHK $141.64
- LEGN $77.09
- AVG Volume (30 Days)
- MHK 756.1K
- LEGN 2.0M
- Earning Date
- MHK 07-24-2025
- LEGN 08-08-2025
- Dividend Yield
- MHK N/A
- LEGN N/A
- EPS Growth
- MHK N/A
- LEGN N/A
- EPS
- MHK 7.66
- LEGN N/A
- Revenue
- MHK $10,683,300,000.00
- LEGN $728,303,000.00
- Revenue This Year
- MHK N/A
- LEGN $65.49
- Revenue Next Year
- MHK $3.03
- LEGN $53.76
- P/E Ratio
- MHK $12.97
- LEGN N/A
- Revenue Growth
- MHK N/A
- LEGN 112.46
- 52 Week Low
- MHK $96.24
- LEGN $27.34
- 52 Week High
- MHK $164.29
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- MHK 43.11
- LEGN 53.16
- Support Level
- MHK $97.69
- LEGN $33.84
- Resistance Level
- MHK $104.02
- LEGN $35.29
- Average True Range (ATR)
- MHK 2.85
- LEGN 1.96
- MACD
- MHK -0.24
- LEGN 0.24
- Stochastic Oscillator
- MHK 23.91
- LEGN 52.16
About MHK Mohawk Industries Inc.
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States, while it also operates in Latin America, Europe and Others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.